Neuro-ophthalmic Complications in Patients Treated with CTLA-4 and PD-1/PD-L1 Checkpoint Blockade Inhibition (Slides)

Update Item Information
Identifier 20200309_nanos_sciplatform1_05-slides
Title Neuro-ophthalmic Complications in Patients Treated with CTLA-4 and PD-1/PD-L1 Checkpoint Blockade Inhibition (Slides)
Creator Eduardo Nicolás Seleme; Michel Sun; John Chen; Anastasia Zekeridou; Elia Sechi; Ryan Walsh; Johanna Beebe; Osama Sabbagh; Luis Mejico; Sean Gratton; Philip Skidd; David Bellows; Julie Falardeau; Clare Fraser; Cecilia Cappelen-Smith; Scott Haines; Bahareh Hassanzadeh; Meagan Seay; Prem Subramanian; Zoë Williams; Lynn Gordon
Affiliation (ENS) (MS) (LG) Jules Stein Eye Institute, David Geffen School of Medicine, UCLA, Los Angeles, California; (JC) Department of Ophthalmology, MayoClinic Department of Neurology, Mayo Clinic, Rochester, Minnesota; (AZ) (ES) Department of Neurology, Mayo Clinic, Rochester, Minnesota; (RW) Department of Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin; (JB) Department of Ophthalmology, Park Nicollet Health Services, Minneapolis, Minnesota; (OS) Department of Ophthalmology, University of Kentucky/Retina Associates of Kentucky, Lexington, Kentucky; (LM) Department of Ophthalmology, SUNY Upstate Medical University, Syracuse, New York; (SG) Department of Neurology, University of Missouri-Kansas City, Kansas City, Montana; (PS) Department of Ophthalmology, University of Vermont Medical Center, Burlington, Vermont; (DB) The Medical Eye Center, Manchester, New Hampshire; (JF) Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon; (CF) Department of Ophthalmology, University of Sydney, Sydney, Australia; (CC) Department of Neurology & Neurophysiology, Liverpool Hospital, NSW, Australia; (SH) Department of Neurology, Virginia Commonwealth University School of Medicine, Richmond, Virginia; (BH) Department of Neurology and Ophthalmology, INI Eye center, University of Illinois, Peoria, Illinois; (MS) Department of Ophthalmology, University of Utah, Salt Lake City, Utah; (PS) Department of Ophthalmology, University of Colorado, Aurora, Colorado; (ZW) Department of Ophthalmology, University of Rochester Medical Center, Rochester, New York
Subject Optic Neuritis; Myasthenia; Ocular Motility; Orbit; Chemotherapy and Radiation Injury
Description In recent years, the use of CTLA-4 and PD-1/PD-L1 checkpoint blockade inhibitors have proven to be effective and become increasingly widespread treatment options for metastatic melanoma and other cancers by enhancing autologous anti-tumor immune responses. Immune related ophthalmologic complications have been reported in association with checkpoint inhibitor usebut remain incompletely characterized. This study seeks to investigate and further characterize the Neuro-ophthalmic adverse effects from immune checkpoint blockade treatment.
Date 2020-03
Language eng
Format application/pdf
Format Creation Microsoft PowerPoint
Type Text
Source 2020 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2020: Scientific Platform Session I
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2020. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6kh5x58
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Setname ehsl_novel_nam
ID 1541334
Reference URL https://collections.lib.utah.edu/ark:/87278/s6kh5x58
Back to Search Results